^
Association details:
| Biomarker: | RHOA G17V |
|---|---|
| Cancer: | T Cell Non-Hodgkin Lymphoma |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Dasatinib Is an Effective Treatment for Angioimmunoblastic T-cell Lymphoma
Published date:
05/01/2020
Excerpt:
A partial response (PR) was achieved in all remaining patients (1, 3, 4, and 5) after 30 days of dasatinib treatment, based on commonly used response criteria...Among the 4 patients that responded to dasatinib in the clinical part of this study, two harbored G17V RHOA mutations and one exhibited VAV1 mutations. These 3 patients' responses support our hypothesis that dasatinib is a candidate drug to treat tumors harboring G17V RHOA mutations.
DOI:
10.1158/0008-5472.CAN-19-2787
